info@seagull-health.com
SeagullHealth
语言:
search
new
Dosage Overview: Selumetinib
500
Article source: Seagull Pharmacy
Jun 24, 2025

Selumetinib is a targeted drug specifically designed for the treatment of neurofibromatosis type 1 (NF1)-associated plexiform neurofibromas (PN). This article will provide a detailed description of the dosage of Selumetinib, precautions for use, and the dietary structure that patients should adopt to help patients and their families better understand and use the drug.

Selumetinib dosage

Following your doctor's guidance for dose adjustments is important to maintain efficacy and reduce side effects.

Recommended dose

The recommended dose of Selumetinib is given by body surface area (BSA) at a single recommended dose of 25 mg/m² orally twice daily (approximately every 12 hours). The dose administered is calculated individually based on body surface area and rounded to the nearest dose of 5 mg or 10 mg (the maximum dose for a single dose is 50 mg).

Missed dose management and vomiting coping

If you forget to take the medication, you can only take it if it is more than 6 hours before the next dose. If vomiting occurs after taking the drug, no additional supplemental dose is required and the next dose should be given as planned.

Proper management of missed doses and response to vomiting can help maintain stable blood levels and improve treatment outcomes.

Dose adjustment regimen

Considering individual safety and tolerability, Selumetinib may need to be suspended, tapered, or permanently discontinued. A specialist should be consulted for specific taper regimens, and the patient's response should be monitored regularly.

By regularly assessing the patient's response and adjusting the treatment regimen accordingly, the treatment effect can be optimized and adverse effects can be reduced.

Precautions for Selumetinib

Paying close attention to changes in heart function and adjusting treatment strategies in a timely manner can help prevent serious heart complications. Regular eye exams and early detection of vision problems can effectively manage the risk of visual toxicity.

Cardiomyopathy surveillance

Left ventricular ejection fraction (LVEF) should be assessed by echocardiography prior to initiation of treatment, every three months for the first year of treatment, and every six months thereafter, and as clinically indicated. If the LVEF is less than ≥10% of baseline, Selumetinib should be suspended, reduced, or permanently discontinued.

See-to-toxicity management

Selumetinib may cause serious visual toxicity, including retinal vein occlusion (RVO) and retinal pigment epithelium detachment (RPED). It is recommended to have a full ophthalmologic evaluation before initiating treatment and at regular intervals during treatment to assess changes in visual acuity.

Gastrointestinal toxicity and skin toxicity

Selumetinib may cause gastrointestinal toxicity (e.g., diarrhea, colitis, etc.) and skin toxicity (e.g., skin rash, acne-like rash, etc.). Take antidiarrheal drugs (such as loperamide) immediately when unformed loose stools occur and increase fluid intake; Monitor for severe rashes.

Proactive management and coping with these common side effects not only reduces patient discomfort but also improves treatment adherence.

Diet of Selumetinib patients

A healthy diet can help improve overall health and support the body's needs during treatment. Adequate protein intake can help promote wound healing and support the immune system.

The importance of a balanced diet

While receiving Selumetinib treatment, patients should maintain a balanced diet and increase their intake of antioxidant-rich foods such as fresh fruits and vegetables to boost the immune system. Avoid foods high in fat and sugar, which may add to the burden on the body.

Protein intake

Protein is important for repairing tissues and maintaining muscle mass. Patients should increase their intake of high-quality proteins, such as lean meats, fish, legumes, and nuts.

Hydration

Maintaining adequate water intake is important for maintaining normal metabolism and detoxification of the body. Increasing fluid intake is especially important when gastrointestinal side effects such as diarrhea occur.

Adequate hydration will not only help alleviate side effects, but also maintain good physical condition.

Note: For internal discussion among medical personnel only. For specific medication, please consult the attending physician. Drug information may change over time. For the latest information, we recommend adding a medical consultant or consulting for free online.
Selumetinib(Koselugo)
Selumetinib(Koselugo)
KOSELUGO (selumetinib) is indicated for the treatment of pediatric patients...
WeChat Scan
Free Inquiry
Recommended Articles
The efficacy of the neurofibromatosis type 1 drug Selumetinib and the management of precautions
Selumetinib is the first and only drug approved in China for the treatment of pediatric patients with neurofibromatosis type 1 (NF1) with symptomatic and inoperable plexiform neurofibromas (PN), ...
Instructions for Selumetinib: action and efficacy, dosage, side effects, precautions
Selumetinib is a MEK1/2 inhibitor developed by AstraZeneca and approved by the US FDA in April 2020 for the treatment of neurofibromatosis type 1 (NF1)-associated plexiform neurofibromas in child...
Side effects of Selumetinib
Selumetinib is a MEK1/2 inhibitor that has shown promising efficacy in the treatment of neurofibromatosis type 1 (NF1)-associated plexiform neurofibromas, but also comes with a specific risk of s...
Adverse reactions caused by Selumetinib bisulfate capsules
The U.S. FDA Approved Selumetinib (Koselugo) for the Treatment of Pediatric Patients 2 years of age and older with Neurofibromatosis Type 1 (NF1) and Symptomatic, Inoperable Plexiform Neurofibromas (P...
Introduction to Metyrapone in the treatment of Cushing syndrome (CS)
Metyrapone, also known as Metyrapone, is a medication used to treat Cushing's syndrome (CS). It helps control the symptoms of Cushing's syndrome by inhibiting the enzyme 11β-hydroxylase (CYP11...
Indications for Metyrapone
Metyrapone is a drug specifically used to diagnose adrenal insufficiency, and its scope of use, contraindications, and interactions with other drugs are key information that must be understood du...
What diseases is Metyrapone suitable for?
As an important pharmaceutical ingredient, Metyrapone has a wide range of applications in the medical field. This article will elaborate on the indications, recommended dosage, and precautions fo...
Metyrapone is effective in treating what diseases
Metyrapone is an adrenal steroid synthesis inhibitor, which has a good clinical effect on the clinical treatment of adrenal insufficiency, adrenal tumors, Cushing's syndrome and other disease...
Related Articles
How to Purchase Selumetinib (Koselugo)
Selumetinib (Koselugo) is a MEK1/2 kinase inhibitor specifically indicated for the treatment of symptomatic, inoperable plexiform neurofibromas (PN) in pediatric patients aged 1 year and older with ne...
How to Use Selumetinib (Koselugo)
Selumetinib (Koselugo) is a MEK1/2 kinase inhibitor that plays a key role in the treatment of symptomatic, inoperable plexiform neurofibromas (PN) associated with neurofibromatosis type 1 (NF1) in chi...
What is Selumetinib (Koselugo)?
Selumetinib (Koselugo) is a kinase inhibitor primarily used for the treatment of specific types of nervous system tumors. As a targeted therapy drug, its unique pharmacological effects provide an impo...
What is Selumetinib (Koselugo)?
Selumetinib (Koselugo) is a targeted therapeutic drug for diseases caused by specific gene mutations. Developed by AstraZeneca, it was first approved for marketing by the U.S. FDA in 2020.What is Selu...
Dosage Overview: Selumetinib
Selumetinib is a targeted drug specifically designed for the treatment of neurofibromatosis type 1 (NF1)-associated plexiform neurofibromas (PN). This article will provide a detailed description ...
The efficacy of the neurofibromatosis type 1 drug Selumetinib and the management of precautions
Selumetinib is the first and only drug approved in China for the treatment of pediatric patients with neurofibromatosis type 1 (NF1) with symptomatic and inoperable plexiform neurofibromas (PN), ...
Instructions for Selumetinib: action and efficacy, dosage, side effects, precautions
Selumetinib is a MEK1/2 inhibitor developed by AstraZeneca and approved by the US FDA in April 2020 for the treatment of neurofibromatosis type 1 (NF1)-associated plexiform neurofibromas in child...
Side effects of Selumetinib
Selumetinib is a MEK1/2 inhibitor that has shown promising efficacy in the treatment of neurofibromatosis type 1 (NF1)-associated plexiform neurofibromas, but also comes with a specific risk of s...
New Drugs
Infigratinib(Truseltiq)
Infigratinib(Truseltiq)
Treatment of previously treated, unresectable locally advanced or metastatic...
Opicapone(Ongentys)
Opicapone(Ongentys)
Adjunctive treatment to levodopa/carbidopa for reducing "off" episodes in...
Deflazacort(Emflaza)
Deflazacort(Emflaza)
Treatment of Duchenne muscular dystrophy (DMD) in patients aged 2 years and...
Faricimab-svoa(Vabysmo)
Faricimab-svoa(Vabysmo)
Treatment of neovascular age-related macular degeneration, diabetic macular...
Counselling Service
Global Drug Search
Clinical Research Recruitment
Overseas Medical Treatment
Remote Consultations
Note: Our medical consultant will contact you as soon as possible. We promise to strictly protect your privacy.
Submit
Business
  • Core products
  • Antitumor drugs
  • General drug
  • Antiviral drugs
  • Biological agents
Contact Us 
  • mailbox:info@lucius.la
Welcome to consult
ucius Pharmaceuticals (Lao) Co.,Ltd All rights reserved